NEW YORK, NY / ACCESSWIRE / September 20, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
KRBP Shareholders Click Here: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=31980&wire=1
HGEN Shareholders Click Here: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=31980&wire=1
MDT Shareholders Click Here: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=31980&wire=1
* ADDITIONAL INFORMATION BELOW *
Kiromic BioPharma, Inc. (NASDAQ:KRBP)
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock between June 25, 2021 and August 13, 2021, both dates inclusive.
Lead Plaintiff Deadline : October 4, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kiromic-lawsuit-submission-form?prid=31980&wire=1
The complaint alleges that the registration statement and prospectus issued in connection with the Company's public offering that closed on July 2, 2021 (the 'Offering Documents') failed to disclose that the Food and Drug Administration ('FDA') had, prior to the filing of these documents, imposed a clinical hold on the Company's Investigational New Drug ('IND') applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
Humanigen, Inc. (NASDAQ:HGEN)
HGEN Lawsuit on behalf of: investors who purchased May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline : October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=31980&wire=1
According to the filed complaint, during the class period, Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Medtronic plc (NYSE:MDT)
This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.
Lead Plaintiff Deadline : November 7, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/medtronic-class-action-loss-submission-form?prid=31980&wire=1
According to the filed complaint, (1) Medtronic's product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company's misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company's need to improve its quality control systems, would negatively affect the Company's financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: https://www.accesswire.com/716775/CLASS-ACTION-UPDATE-for-KRBP-HGEN-and-MDT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders